Thus, inhibition of the NF-κβ and STAT3 factors appears to be associated with clinical benefits in IBD, where the inhibition of persistent activation of STAT3 by NF-κβ may be an alternative in explaining the pathogenesis and treatment of colorectal cancer associated with colitis [44]. This evidence concerns the gene NFKB1 and inflammatory bowel disease.